US Dollar vs MXN

Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.

Regístrate

BMY Bristol Myers Squibb Co

43.99

0.29 (0.66%)

03 May 2024 - Cerrado

Retrasado por 15 minutos

Form 3 - Initial statement of beneficial ownership of securities

Bristol Myers Squibb (NYSE:BMY)
Gráfica de Acción Histórica
De Abr 2024 a May 2024

Haga Click aquí para más Gráficas Bristol Myers Squibb.

Bristol Myers Squibb (NYSE:BMY)
Gráfica de Acción Histórica
De May 2023 a May 2024

Haga Click aquí para más Gráficas Bristol Myers Squibb.

Noticias sobre Bristol Myers Squibb Co BMY

Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration
Miércoles 1 de Mayo 2024 (4 días hace) • GlobeNewswire Inc.

Repertoire® Immune Medicines and Bristol Myers Squibb Announce Multi-Year Strategic Collaboration to Develop Tolerizing Vaccines for Autoimmune Diseases
Lunes 29 de Abril 2024 (6 días hace) • PR Newswire (US)

CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb’s Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
Viernes 26 de Abril 2024 (1 semana hace) • Business Wire

U.S. Futures Drop in Pre-Market Trading as Tech Stocks Plunge After Meta Issues Gloomy Forecast
Jueves 25 de Abril 2024 (1 semana hace) • IH Market News

Bristol Myers Squibb Reports First Quarter Financial Results for 2024
Jueves 25 de Abril 2024 (1 semana hace) • Business Wire

Apple Loses Market Share in China, GM Surges in Pre-Market Following Upward Revisions for 2024 Projections, and More News
Martes 23 de Abril 2024 (2 semanas hace) • IH Market News

Bristol Myers Squibb and Cellares Announce a $380M Worldwide Capacity Reservation and Supply Agreement for the Manufacture of CAR T Cell Therapies to Bring the Promise of Cell Therapy to More Patients, Faster
Lunes 22 de Abril 2024 (2 semanas hace) • Business Wire

KRAZATI (adagrasib) in Combination with Cetuximab Demonstrates Clinically Meaningful Activity as a Targeted Treatment Option for Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)
Lunes 8 de Abril 2024 (4 semanas hace) • Business Wire

Bristol Myers Squibb Presents New Interim Long-Term Efficacy Data from the EMERGENT-4 Trial Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research Society
Sábado 6 de Abril 2024 (4 semanas hace) • Business Wire

U.S. FDA Approves Bristol Myers Squibb and 2seventy bio’s Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy
Viernes 5 de Abril 2024 (1 mes hace) • Business Wire

European Commission Expands Approval of Bristol Myers Squibb’s Reblozyl® (luspatercept) to Include First-Line Treatment of Transfusion-Dependent Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (LR-MDS)
Martes 2 de Abril 2024 (1 mes hace) • Business Wire

Bristol Myers Squibb Releases 2023 Environmental, Social and Governance Report Demonstrating Progress and Setting New Long-Term Goals
Martes 2 de Abril 2024 (1 mes hace) • Business Wire

Más de Bristol Myers Squibb Co Artículos de Noticias

Gold vs US Dollar

Deutsche Telekom (QX)

Delayed Upgrade Clock

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones